Get the Stockscreener App
72.47
1.74%
1.24
After Hours:
72.00
-0.47
-0.65%
Dexcom Inc stock is traded at $72.47, with a volume of 8.53M.
It is up +1.74% in the last 24 hours and up +11.34% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$71.23
Open:
$72.61
24h Volume:
8.53M
Relative Volume:
1.57
Market Cap:
$27.96B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
31.00
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
-3.69%
1M Performance:
+11.34%
6M Performance:
+9.95%
1Y Performance:
-10.54%
1-Day Range:
$71.60
$73.69
1-Week Range:
$70.90
$76.25
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
72.47 | 27.96B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
Dexcom StockThursday technicals and trading range - AD HOC NEWS
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound - Investing.com
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom (DXCM) EVP Michael Jon Brown sells 1,700 shares in pre-set 10b5-1 trade - Stock Titan
Dexcom (NASDAQ: DXCM) director’s family trust sells 4,000 shares under 10b5-1 plan - Stock Titan
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
Dexcom Inc (DXCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dexcom Inc (DXCM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dexcom Inc (DXCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Dexcom Inc (DXCM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
[144] DEXCOM INC SEC Filing - Stock Titan
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Michael Brown files sale notice — Michael Brown (NASDAQ: DXCM) seeks to sell 1,700 shares - Stock Titan
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor - Benzinga
In a first, Dexcom’s OTC glucose sensor is cleared for kids - MedTech Dive
DexCom, Inc. (DXCM) Stock Analysis: Exploring a 13% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
DexCom’s quarterly earnings preview: What you need to know - MSN
How G7 CONNECT Trial Results at DexCom (DXCM) Have Changed Its Investment Story - Sahm
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
DexCom (DXCM) Launches First Over-the-Counter Glucose Monitor fo - GuruFocus
Dexcom (DXCM) Launches First OTC Glucose Monitor for Children - GuruFocus
FDA clears first over-the-counter glucose monitor for children - marketscreener.com
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom Expands Beyond CGMs With CONNECT Results AI Apps And Nutrisense Deal - Yahoo Finance
Lyell Wealth Management LP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
Vestal Point Capital, LP's DexCom Inc(DXCM) Holding History - GuruFocus
A Watch on DexCom: Expanding Access and Innovation Drive the Next Chapter of CGM Leadership - Kalkine
3 Reasons Investors Love DexCom (DXCM) - Yahoo Finance
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction - Reuters
Goodman Advisory Group LLC Invests $1.29 Million in DexCom, Inc. $DXCM - MarketBeat
DexCom Says Diabetes Tech Issue Isn't Investor Fraud - Law360
TD Cowen Remains a Buy on Dexcom (DXCM) - The Globe and Mail
Dexcom Inc. stock (US2521311074): TD Cowen lifts target after strong Q1 momentum - AD HOC NEWS
TD Cowen raises DexCom stock price target to $95 on data - Investing.com UK
TD Cowen Adjusts Price Target on DexCom to $95 From $75, Maintains Buy Rating - marketscreener.com
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
Motley Fool Asset Management LLC Raises Stake in DexCom, Inc. $DXCM - MarketBeat
DexCom Inc (DXCM)'s Winning Formula: Financial Metrics and Compe - GuruFocus
Is DexCom stock underperforming the Dow? - MSN
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom stock (US2521311074): Mizuho lifts target after diabetes study - AD HOC NEWS
Pumps, patches and fixes at the ADA - BioWorld News
Dexcom bolsters evidence for glucose sensors for Type 2 diabetes - MedTech Dive
Devon Energy Corp stock (US2521311074): Dividend, oil price moves and what matters for investors - AD HOC NEWS
Mizuho raises Dexcom stock price target to $85 on diabetes study - Investing.com
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jun 15 '26 |
Sale |
74.13 |
4,000 |
296,540 |
52,852 |
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):